An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever.

Clicks: 227
ID: 32109
2007
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #1,485 of 2,056 articles by views in PloS one

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 2,056 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
To assess the efficacy of gatifloxacin versus cefixime in the treatment of uncomplicated culture positive enteric fever.A randomized, open-label, active control trial with two parallel arms.Emergency Room and Outpatient Clinics in Patan Hospital, Lagankhel, Lalitpur, Nepal.Patients with clinically diagnosed uncomplicated enteric fever meeting the inclusion criteria.Patients were allocated to receive one of two drugs, Gatifloxacin or Cefixime. The dosages used were Gatifloxacin 10 mg/kg, given once daily for 7 days, or Cefixime 20 mg/kg/day given in two divided doses for 7 days.The primary outcome measure was fever clearance time. The secondary outcome measure was overall treatment failure (acute treatment failure and relapse).Randomization was carried out in 390 patients before enrollment was suspended on the advice of the independent data safety monitoring board due to significant differences in both primary and secondary outcome measures in the two arms and the attainment of a priori defined endpoints. Median (95% confidence interval) fever clearance times were 92 hours (84-114 hours) for gatifloxacin recipients and 138 hours (105-164 hours) for cefixime-treated patients (Hazard Ratio[95%CI] = 2.171 [1.545-3.051], p<0.0001). 19 out of 70 (27%) patients who completed the 7 day trial had acute clinical failure in the cefixime group as compared to 1 out of 88 patients (1%) in gatifloxacin group(Odds Ratio [95%CI] = 0.031 [0.004 - 0.237], p<0.001). Overall treatment failure patients (relapsed patients plus acute treatment failure patients plus death) numbered 29. They were determined to be (95% confidence interval) 37.6 % (27.14%-50.2%) in the cefixime group and 3.5% (2.2%-11.5%) in the gatifloxacin group (HR[95%CI] = 0.084 [0.025-0.280], p<0.0001). There was one death in the cefixime group.Based on this study, gatifloxacin is a better treatment for uncomplicated enteric fever as compared to cefixime.Current Controlled Trials ISRCTN75784880.
Reference Key
pandit2007anplos Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Pandit, Anil;Arjyal, Amit;Day, Jeremy N;Paudyal, Buddhi;Dangol, Sabina;Zimmerman, Mark D;Yadav, Bharat;Stepniewska, Kasia;Campbell, James I;Dolecek, Christiane;Farrar, Jeremy J;Basnyat, Buddha;
Journal PloS one
Year 2007
DOI
DOI not found
URL
http://europepmc.org/articles/PMC1891439?pdf=render
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.